指南与共识乳腺癌

BRCA1和BRCA2基因检测临床实践指南

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
指南 / 共识 · Eur J Cancer · 2021-02-10

法国预测与个性化医学学会(SFMPP)委托国际专家组制定BRCA1/2基因检测综合指南,基于系统文献回顾、风险评估模型和专家意见评估BRCAm可能性及PARP抑制剂治疗价值,旨在更新和标准化BRCA检测实践。

要点

  • 识别可能受益于遗传咨询和降风险策略的个体。
  • 更新PARP抑制剂获批治疗相关的胚系和肿瘤检测指征。
  • 提供早期和转移性乳腺癌个性化管理的检测建议。

核心结论

  • 该国际指南有助于临床医生全面更新和标准化BRCA检测实践。

研究设计与样本

  • 由法国预测与个性化医学学会(SFMPP)委托的国际专家组制定,成员包括遗传学家、肿瘤内科和外科肿瘤学家、病理学家、伦理学家和患者代表。
  • 采用特定正式指南制定方法,包括基于系统文献回顾、风险评估模型和专家引文的BRCAm可能性评估,以及BRCAm状态对PARP抑制剂治疗和乳腺癌管理的治疗价值评估。

关键数值与推荐

  • 识别可能受益于遗传咨询和降风险策略的个体。
  • 更新PARP抑制剂获批治疗相关的胚系和肿瘤检测指征。
  • 提供早期和转移性乳腺癌个性化管理的检测建议。
  • 处理快速流程和肿瘤分析的问题。

临床怎么用

  • 用于识别可能受益于遗传咨询和降风险策略的个体。
  • 用于更新PARP抑制剂获批治疗相关的胚系和肿瘤检测指征。
  • 用于早期和转移性乳腺癌个性化管理的检测建议。
  • 用于处理快速流程和肿瘤分析的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed. The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis. An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer. These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pujol P, Barberis M, Beer P, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021. PMID: 33578357. doi:10.1016/j.ejca.2020.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。